G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 26.45 SEK -3.47%
Market Cap: 1.7B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genovis AB
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
G
Genovis AB
STO:GENO
Other Current Liabilities
kr16.3m
CAGR 3-Years
7%
CAGR 5-Years
9%
CAGR 10-Years
11%
AddLife AB
STO:ALIF B
Other Current Liabilities
kr490m
CAGR 3-Years
14%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Other Current Liabilities
kr378.6m
CAGR 3-Years
120%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Other Current Liabilities
kr546m
CAGR 3-Years
37%
CAGR 5-Years
89%
CAGR 10-Years
52%
MedCap AB (publ)
STO:MCAP
Other Current Liabilities
kr41.9m
CAGR 3-Years
41%
CAGR 5-Years
30%
CAGR 10-Years
16%
M
Magle Chemoswed Holding AB
STO:MAGLE
Other Current Liabilities
kr13.5m
CAGR 3-Years
12%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
No Stocks Found

Genovis AB
Glance View

Market Cap
1.7B SEK
Industry
Life Sciences Tools & Services

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

GENO Intrinsic Value
25.55 SEK
Overvaluation 3%
Intrinsic Value
Price
G

See Also

What is Genovis AB's Other Current Liabilities?
Other Current Liabilities
16.3m SEK

Based on the financial report for Jun 30, 2024, Genovis AB's Other Current Liabilities amounts to 16.3m SEK.

What is Genovis AB's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
11%

Over the last year, the Other Current Liabilities growth was 1%. The average annual Other Current Liabilities growth rates for Genovis AB have been 7% over the past three years , 9% over the past five years , and 11% over the past ten years .

Back to Top